TargetMol

Telaglenastat

Product Code:
 
TAR-T6797
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T6797-5mg5mg£108.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6797-1mL1 mL * 10 mM (in DMSO)£118.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6797-10mg10mg£128.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6797-25mg25mg£173.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6797-50mg50mg£249.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6797-100mg100mg£367.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6797-500mg500mg£768.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
CB-839(IC50 of 24 nM), an effective, specific, and oral inhibitor, which is bioavailable glutaminase, for recombinant human GAC.
CAS:
1439399-58-2
Formula:
C26H24F3N7O3S
Molecular Weight:
571.58
Pathway:
Autophagy; Metabolism; Proteases/Proteasome
Purity:
0.9989
SMILES:
FC(F)(F)Oc1cccc(CC(=O)Nc2ccc(CCCCc3nnc(NC(=O)Cc4ccccn4)s3)nn2)c1
Target:
transporter; Glutaminase; Autophagy

References

Caiola E, Colombo M, Sestito G, et al. Glutaminase Inhibition on NSCLC Depends on Extracellular Alanine Exploitation. Cells. 2020, 9(8): 1766 Gross MI, et al. Mol Cancer Ther. 2014, 13(4):890-901. Caiola E, Colombo M, Sestito G, et al. Glutaminase Inhibition on NSCLC Depends on Extracellular Alanine Exploitation[J]. Cells. 2020, 9(8): 1766.